Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This inhibition reduces the synthesis of DNA, RNA, and proteins, limiting the proliferation of rapidly dividing cells, including immune cells and cancer cells, thereby providing immunosuppressive and antiproliferative effects.

The dosage of Methofill is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Patients should follow the exact dosing schedule provided by their healthcare professional and not adjust the dose on their own.

Methofill is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause severe fetal malformations or death. It is also not recommended during breastfeeding, as methotrexate can be excreted in breast milk and may harm the infant. Effective contraception is required for both men and women receiving the drug.

To place an order, visit the product page for Methofill on gnhindia.com, enter the required quantity, and submit the inquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

For rheumatoid arthritis, Methofill (methotrexate) is often the first‑line disease‑modifying antirheumatic drug (DMARD) and is less expensive than many biologic agents. In oncology, it offers a non‑targeted chemotherapy option that can be combined with newer agents. Compared with newer oral DMARDs, methotrexate has a longer safety record but requires regular monitoring of liver and blood parameters.

Methofill should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the product. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and return it to refrigeration promptly.

Methofill is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose using a suitable needle and syringe, typically into the abdomen or thigh. The injection site should be rotated to reduce local irritation, and patients should be instructed on proper aseptic technique if self‑administration is approved.

The most critical adverse events include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and life‑threatening infections. Renal failure and rare severe skin reactions such as Stevens‑Johnson syndrome may also occur. Prompt recognition and medical evaluation of these signs are essential for patient safety.

Methofill is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate or any component of the formulation, patients with severe hepatic impairment, uncontrolled infections, and those with significant renal dysfunction. Caution is also advised for patients with pre‑existing lung disease or a history of severe bone‑marrow suppression.